Chief Medical Officer, Prostatype Genomics
Joined October 2009
- Tweets390
- Following951
- Followers1.8K
- Likes1.3K
Finally an improved biopsy needle! #Xagasurgical #AUA2026 #Booth2863
Better targeting and reduced bacterial transfer
Gerald Andriole, MD retweeted
A toast 🥂 to the 50th Anniversary of the Winter Urologic Forum! 💫
Always a great meeting!
@ColumbiaUrology @UCDavisUrology
Vanderbilt Urology
Gerald Andriole, MD retweeted
Phase 1 study evaluates bone metastasis resolution with SYNC-T therapy SV-102. @uropro @ProstatypeAB joins @zklaassen_md @GACancerCenter SYNC-T therapy SV-102 for metastatic prostate cancer. The treatment combines one-minute cryolysis of tumor tissue with immediate infusion of a four-component immunoadjuvant to generate tumor-specific T cell responses. #WatchNow > bit.ly/3MuSxKr
Prostatype P-score demonstrated superb risk classification of Prostate Cancer in a diverse US population. Very useful tool for men considering Active Surveillance and the intensity of surveillance. Low risk men had no PCSM! @nature.com/pcan/
Gerald Andriole, MD retweeted
Thank you #SUO25. We were proud to share Phase 1 SYNC-T data showing 54% of metastatic prostate cancer patients had complete resolution of bone metastases and favorable tolerability.
SYNC-T is now being studied for mCRPC in the Phase 2 LEGION-100 trial.
Details: bit.ly/48jYaU5
Gerald Andriole, MD retweeted
#SUO25 @uropro presents SYNC-T SV-102 for mPCa
🧬 Image-guided intratumoral immunotherapy targeting 4 immune axes
👥 n=15 (Phase 1) | post-ARPI or hormone-declined | bone mets in 87%
🔹 ORR: 87% | CR: 53%
🔹 Bone mets resolved in 7/13 pts incl. >50 lesions in 1 case
🛡️ 95% Grade 1–2 AEs | no Gr 4/5
✅ Early signal for durable, systemic immunity via local delivery
@UroToday @UroOnc
Gerald Andriole, MD retweeted
Syncromune® Inc. Presents Positive Results from SYNC-T® Therapy SV-102 Phase 1 Metastatic Prostate Cancer Trial at ASCO 2025
- 87% ORR
- 53% CR
- 100% DCR
- 14.2 months rPFS
- 80% survival after 17.2 month median follow-up
globenewswire.com/news-relea…
Gerald Andriole, MD retweeted
Stop by the Syncromune booth at #ASCO25 to learn more about our LEGION-100 Phase 2a trial of SYNC-T Therapy SV-102 for #mCRPC. Now enrolling and recruiting clinical trial sites. #LEGION100 #ProstateCancer
Gerald Andriole, MD retweeted
Syncromune® Inc. Announces Publication of Abstract on SYNC-T® Therapy SV-102 Phase 1 Data for Metastatic Prostate Cancer at ASCO 2025 Annual Meeting #ASCO25 globenewswire.com/news-relea…
Gerald Andriole, MD retweeted
So inspired to be collaborating with an incredible team of experts in bladder cancer. Excited for the impactful work we’ll do together transforming early detection!
prn.to/3yI2PQy
@UroCancerMD @pcvblack @SimaPorten @siadaneshmand @ctleeuro @garysteinbergmd @ylotan
Prostatype Genomics receives CAP laboratory accreditation, achieves another milestone towards entering the US market prostatypegenomics.com/cisio…
Prostatype Genomics AB US subsidiary Prostatype Genomics, Inc. has been accredited by the CAP (College of American Pathologists) Laboratory Accreditation Program!